Ebola has crippled the provision of treatment and care to people living with HIV/AIDS in Liberia, according to health workers and patients.
5 hours ago | IRIN
Exposing the trade in stolen drugs that is costing the lives of tens of thousands of HIV/AIDS sufferers in Zimbabwe.
6 hours ago | Al Jazeera (video)
Despite many efforts to fight racial disparities in HIV rates among men who have sex with men (MSM), black MSM will likely continue to have disproportionately high HIV rates for decades. A modeling analysis projects how varying rates of HIV testing and retention in HIV care would affect racial disparities between black and white MSM.
21 November 2014 | AIDSMeds
The Petrelis Files blog looks at the CDC audit of the National Association of People With AIDS (NAPWA), which declared bankruptcy and closed in 2013.
21 November 2014 | Poz magazine news
The world's leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday. GSK tops the Index for the fourth time. This is driven by robust performance across most areas, with several innovative practices. Novo Nordisk has made the most progress, improving in five of the seven areas the Index focuses on. This has resulted in a remarkable leap from 6th to 2nd place. Sanofi and Pfizer fell down the ranking most significantly.
18 November 2014 | Access to Medicine Index
I am not going to be here for the cure. I am not going to see the end of AIDS. And neither will you.
17 November 2014 | The Body
South Africa has the ability and resolve to overcome the challenge of the HIV/AIDS epidemic, Deputy President Cyril Ramaphosa said on Saturday.
11 November 2014 | AllAfrica.com
With change comes both opportunity and chaos: an assertion nowhere more true than with England's addiction services. Over the past 5 years, government initiatives to increase cost-effectiveness have opened up bidding for local services to third-party providers. With increased competition, the thinking went, bloated NHS trusts would sharpen their edges and the quality of care would be improved.
10 November 2014 | The Lancet Psychiatry
Fewer than half of patients who tested HIV-positive at a Johannesburg, South Africa clinic returned to complete eligibility testing for antiretroviral therapy (ART), suggesting that “strategies to reduce attrition from all stages of care are urgently needed,” a new study led by a BU researcher finds.
07 November 2014 | Boston University press release
FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.
07 November 2014 | BioPharma Dive